Royalty Report: Drugs, Antibody, Disease – Collection: 222548

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Antibody
  • Disease
  • Therapeutic
  • Drug Discovery
  • Cancer
  • Diagnostic
  • Immune
  • Biotechnology
  • cell therapy
  • Delivery
  • Technical Know How
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 222548

License Grant
Licensee desires to have Licensor conduct research with the Mice for the development of fully human monoclonal antibodies to certain Antigens and to evaluate the utility of such antibodies as potential therapeutics.

For the research license, Licensor grants an exclusive, non-transferable, license solely to use the Antibodies and hybridoma cell lines producing such Antibodies prepared by Licensor in connection with the Research for research and evaluation purposes.

For the commercial license option, Licensee shall have an option to obtain an exclusive, even as to Licensor, worldwide commercial license, solely to develop Antibodies for use in the development and commercialization of Products.

Licensor grants an exclusive, worldwide, non-transferable license under the Licensor Technology with the right to sublicense, to use hybridomas delivered by Licensor to Licensee to make or have made Antibodies, and, an exclusive, worldwide, non-transferable license under the Licensor Technology with the right to sublicense, to use Antibodies made in the Research to make, have made, import, have imported, use, offer for sale and sell Products.

License Property
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.  Mice shall mean immunizable transgenic mice containing un-rearranged human immunoglobulin genes.

The Product shall mean any product for the treatment or diagnosis of human disease containing an Antibody provided by Licensor or produced from any hybridoma provided by Licensor or a portion thereof.

The patents are for Licensors patent rights which claims an invention which is necessary or useful for the use of the Antibodies or the hybridoma cell lines transferred hereunder to make, use or sell Products.

The Antigens are C-proteinase/bone-morphogenic protein,  M-tolloid,  M-tolloid-like (1),  M-tolloid-like (2),   N-proteinase,  Fibril assembly sequences,  Connective tissue growth factor (CTGF),  CTGF receptor, CTGF receptor and/or receptor conjugates which include the CTGF receptor,  An alternative ligand for the CTGF receptor to be named which has not been previously licensed to a third party by Medarex,  CTGF fragments, and,  An alternate CTGF or CCN homolog protein fragment.

Field of Use
This research is for therapeutics for fibrosis or fibroproliferative disease.

'Combining the power of the HuMAb -Mouse technology with the expertise of Licensee a fibrosis industry leader, we have created the opportunity to develop effective anti-fibrotic therapeutics, specifically targeting the unmet areas of chronic organ fibrosis and post-surgical scarring'.

Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This can be a reactive, benign, or pathological state. In response to injury, this is called scarring, and if fibrosis arises from a single cell line, this is called a fibroma.

IPSCIO Record ID: 109479

License Grant
Pursuant to this agreement, to use the Mice to evaluate their utility for the development of fully human monoclonal antibodies to the human CRl complement receptor (CRl) and Staphylococcus aureus, Licensee has the right to exercise an option for a commercial license where Licensor shall grant the following licenses
(a) an exclusive, worldwide, non-transferable license under the Licensors Technology to use the Mice to make Antibodies, and
(b) an exclusive, worldwide license under the Licensors Technology, with the right to sublicense, to use such Antibodies to make, have made, import, have imported, use, offer for sale and sell Products.
License Property
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.

Antibody means a human monoclonal antibody with binding affinity for an Antigen derived by Licensee or its Affiliates or Sublicensees from cells obtained from one or more of the Mice.

Product shall mean any product for the treatment of human disease containing an Antibody with affinity for CRI, or a bispecific antibody consisting of a combination of an Antibody with affinity for CRI and an Antibody to Staphylococcus aureus.

'Mice' shall mean immunizable sterile transgenic mice containing unrearranged human immunoglobulin genes.

Field of Use
This agreement is for the biotechnology industry.  Licensee wishes to acquire from Medarex an option to acquire a commercial license for the use of such monoclonal antibodies to commercialize Products.

IPSCIO Record ID: 222549

License Grant
For the research license, Licensor grants a non-exclusive, non-transferable license, under the Licensor Technology to immunize the Mice to make Antibodies against such Antigen, and to further evaluate the Antibodies generated during the Evaluation Period.

For the commercial license,  Licensor grant the following licenses, on an Licensee Target-by-Licensee Target basis
– a worldwide, exclusive, non-transferable license, with the right to grant a sublicense to its Affiliates, under the Licensor Technology to immunize the Mice to make Antibodies against such Licensee Target, and
– a worldwide exclusive license under the Licensor Technology, with the right to sublicense, to make, have made, import, have imported, use, offer for sale and sell Products containing Antibodies against such Licensor Target.

Licensee shall have no right to grant sublicenses to use the Mice, but may grant sublicenses under
the Licensee Technology to the extent necessary to develop, make, have made, import, use, offer for
sale and sell Products.

License Property
Licensor is the sole and exclusive owner of certain transgenic_ Mice (as defined below) useful for the preparation of fully human monoclonal antibodies;

Licensor Technology includes the Confidential Information and Mice, and patent rights which claims an invention which is necessary for the use of the Mice to prepare the Antibodies or to develop, produce, make, have made, import, have imported, use, offer for sale and sell the Antibodies.

The Product shall mean any composition or formulation comprising one or more Antibodies, or a portion thereof, for the diagnosis, prophylaxis or treatment of human disease.

Licensee Target shall mean an Antigen selected by Licensee for immunization of Licensors HuMAb mice to generate human antibodies directed against an Antigen, in each case, which Licensor has informed Licensee is available for licensing.

HuMAb -Mouse technology is a transgenic mouse system that creates high affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.

Field of Use
Licensee desires to use the Mice to evaluate their utility for the development of fully human monoclonal antibodies against specific antigens.

Incorporating this technology into Licensee's broad drug discovery program will significantly enhance Licensee continuing efforts to identify new drug candidates.

IPSCIO Record ID: 222550

License Grant
Licensee desires Licensor to conduct research with the Mice to generate fully human monoclonal antibodies to certain Antigens.

For the Evaluation License, Licensor grants an exclusive, nontransferable license for the term of the applicable Evaluation Period to use the Collaboration Technology relating to such Antigen solely for the purpose of evaluating whether Licensee shall desire to acquire a commercial license to such Product(s) directed against such Antigen.

For the Option for Commercial Licenses, Licensee shall have an option to obtain a commercial license with respect to Product(s) directed against such Antigen in the Field of Use in all countries of the Territory,

For the Commercial License,  Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensed Technology to make, have made, import, have imported, use, offer for sale and sell Product(s) directed against such Antigen in the Field of Use in the Territory.

For the Research License, Licensee shall have an irrevocable, perpetual, worldwide exclusive research license, without the right to sublicense, to make and use (but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Antibody{ies) and Antibody Cell(s) transferred by Licensor to Licensee, and any related Collaboration Technology, including Genetic Material(s) relating specifically and solely to such Antibody(ies) and Antibody Cell(s), in each case, and an irrevocable, perpetual, worldwide non-exclusive research license, without the right to sublicense, to make and use, but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Collaboration Technology relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, in each case, which is necessary for Licensee to make and use the same for research.

License Property
The patents relate to Transgenic non-human animals capable of producing heterologous antibodies.

The Collaboration Know How shall mean, with respect to each Antigen, any parts or derivatives of the Mice prepared by Licensor in connection with the applicable Immunization and delivered to Licensee, including without limitation, Antibody(ies), Antibody Cell(s), polypeptides, Genetic Material(s) or other biological materials derived directly or indirectly from the Mice delivered to Licensee, all information relating specifically and solely to the foregoing, including without limitation, technical data, protocols and methods and processes with respect to Product(s) directed against such Antigen and, all information relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, including without limitation, technical data, protocols and methods and processes.

Product(s) shall mean, with respect to an Antigen, a composition or compositions with each composition comprising one or more Antibody(ies), Antibody Cell(s) or Genetic Material(s).

Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.

HuMAb -Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies.  Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.

Bispecific antibodies, which enhance and direct the body's own immune system to fight disease; and immunotoxin  technology.

Field of Use
The Field of Use shall mean all uses of Product(s), including all human therapeutic, prophylactic and diagnostic uses of Product(s).

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 942

License Grant
Effective upon Licensee’s election to acquire a commercial license, Licensor grants to Licensee and its Affiliates the following licenses an exclusive, worldwide, non-transferable royalty bearing license under the Licensor Technology with the right to sublicense, to use hybridomas delivered by Licensor to Licensee to make or have made Antibodies, and an exclusive, worldwide, non-transferable royalty bearing license under the Technology with the right to sublicense, to use Antibodies made in the Research to make, have made, import, have imported, use, offer for sale and sell Products.

Product shall mean any product for the treatment or diagnosis of human disease containing an Antibody provided by Licensor or produced from any hybridoma provided by Licensor or a portion thereof.

License Property
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.
Field of Use
Licensee desires to have Licensor conduct research with the Mice for the development of fully human monoclonal antibodies to certain Antigens and to evaluate the utility of such antibodies as potential therapeutics involved in fibrosis or fibroproliferative disease.

IPSCIO Record ID: 383584

License Grant
Licensor grants a worldwide exclusive right and license under Know-how, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products.

Licensor grants an exclusive license under Patent Rights, with respect to Licensors fifty percent ownership interest in such Patent Rights, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products in all jurisdictions outside the United States.

License Property
Licensed Products shall mean Erbitux®, and matuzumab  as well as all derivatives, analogs, fragments, improvements, conjugates and bioequivalents of any of the foregoing.

Erbitux® shall mean cetuximab, and marketed as Erbitux®.

ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a receptor found on both normal and tumor cells that is important for cell growth.

The patent is titled Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.

Field of Use
Erbitux ( cetuximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 256275

License Grant
The Licensor, of England, desires to grant to the Licensee, of Germany, a license on a non-exclusive basis of the right to use the Licensor Licensed Patents for the purpose of researching, developing and commercializing the MT201 Product and other products in respect of he EpCAM target.

For the research license, the Licensor of England grants to the Licensee of Germany a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to perform research and development activities in the Licensee Research Field.

For the commercialization license, Licensor grants a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Licensee Licensed Field.

License Property
Licensor is the owner of rights for certain patents and know-how in the field of Antibody Phage Display.

The know-how includes a Training Manual Antibody Phage Display 2002, and, Licensor mammalian expression lgG vectors.

Licensed Product means the MT201 Product and any other product, substance or formulation arising from the EpCAM Target Program, in each case, the Development, manufacture, importation, use or sale of which would, but for the provisions of this Agreement, infringe one or more Valid Claims under the Licensor Licensed Patents, or utilizes the Licensor Background Know-How.

Field of Use
Licensees Licensed Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the EpCAM Target.

Licensees Research Field means the identification or development of Antibody Products for the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the EpCAM Target.

The excluded field is the discovery, isolation, characterization, research, development, and/pr commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific rationale or activity is neuronal and/or glial mechanisms of action of neuroprotection neurodegenerative conditions, diabetic neuropathy, pain, spinal cord injury, multiple sclerosis, and, stroke as a disease of the cerebrovasculature.

IPSCIO Record ID: 266792

License Grant
The Israeli Licensor, the technology transfer company of the University, grants an exclusive license, with the right to sublicense in two tiers, under All Patents to make, have made, use, sell, offer for sale and import the licensed products.

With this agreement, the Parties wish to resolve all existing and potential claims and outstanding obligations in connection with All Litigation Matters and desire to settle All Litigation Matters on the terms stated herein, without any admission of liability or wrongdoing, in order to avoid the time and expense of continuing to litigate All Litigation Matters.

License Property
The licensed products and related patents are for cetuximab _-C225 (Erbitux®), _-11F8 and all product incorporating the humanized antibody of  ___72000.

Cetuximab is an antibody for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single-agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.

11F8 is a fully-human monoclonal antibody which targets the human EGFR.

__-72000, also known as matuzumab, is a humanized EGFR-targeting monoclonal antibody.

Field of Use
Licensor is a biopharmaceutical company advancing oncology care by developing and commercializing a portfolio of targeted treatments designed to address the medical needs of patients with cancer.

IPSCIO Record ID: 332224

License Grant
Licensor of Israel grants the exclusive right and license, including the right, subject to the Consent Agreement, to sublicense, under the Licensor Technology and Trademarks to Obtain Regulatory Approval, make, have made, use, promote, market, sell, have sold, offer to sell, import or export Products in the Territory.

Licensor grants an exclusive license under its entire right, title and interest in and to the Licensor Trademarks, if any, to use and display the Licensor Trademarks in connection with the Commercialization of Product within the Territory.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
The trademark is HEPEX.

The patents include Human Monoclonal Antibody Against Hepatitis. B Surface Antigen {HBVSAG), and, Treatment of hepatitis B virus infection with human  monoclonal antibodies.

Additional HBV Products shall mean any and all compounds, products, methods or systems, other than a Product or a Directly Competitive Product, in any formulation for the treatment or prevention of Hepatitis 8, that is Controlled by Licensor as of the Effective Date or at any time during the term of this Agreement.

HB/g shall mean the immunoglobulin product containing polyclonal antibodies (derived from human plasma) to hepatitis B surface antigen, and occasionally referred to as HBlg.

HBV Antibody shall mean any and all human or humanized monoclonal immunoglobulins, including intact immunoglobulin molecules and any portion or fragment of an immunoglobulin molecule, such as those portions or fragments commonly known as Fab, Fab, F(ab)2 and F(v), that is directed to and binds to the Hepatitis B virus or any portion of the Hepatitis 8 virus.

HepeX-8 shall mean, without regard to the actual trade name used, any Product containing the human monoclonal antibody [17;1.41., as referred to and described in ECACC Accession No; 96()521.69], and the human monoclonal antibody [19.79.s,; as referred to and described in ECACC Accession No. 96052168], and no other antibodies or fragments of other antibodies.

Field of Use
The field is for use against Hepatitis B.

IPSCIO Record ID: 227238

License Grant
Research License; Supply of Mice; Materials ownership
Licensor hereby grants to Licensee, a Japanese corporation, and the Majority-Owned Affiliates of Licensee, solely as needed to exercise the rights that may be granted, a paid-up, non-exclusive license and/or sublicense of its rights, as the case may be, under the Licensed Technology, without the right to grant further sublicenses, to (i) Breed the XenoMouse Animals included solely for use in the Research Field in connection with activities described in subsections (ii) and (iii) of this Section 2.1.1, (ii) immunize such XenoMouse Animals solely with those Antigens that are Permitted Antigens at the time of immunization and (iii) use the Research Program Materials and Information solely for conducting research and development work within the scope of the Research Field.

Licensor hereby grants to Licensee, and the Majority-Owned Affiliates of Licensee solely as needed to practice the rights that may be granted in accordance with this agreement, a paid-up, non-exclusive license and/or sublicense, as the case may be, of its rights in the Licensor Materials and Information and all intellectual property rights Controlled by Licensor related thereto that are not licensed to Licensee pursuant to the license in subsection (a) above, solely to the extent that the Licensor Materials and Information are necessary or useful to Licensees practice of the license granted in subsection (a) above.

Option to enter into Product License Agreement
Licensor hereby grants to Japanese Licensee an exclusive option (an 'Option') to enter into a Product License Agreement with respect to those Permitted Antigens which have been designated as Product Antigens, as further described. Each calendar year during the term of this Agreement, Licensee may obtain up to Two (2) such Options with respect to Product Antigens, pursuant to the procedures set forth.

License Property
Licensed Technology shall mean the rights Controlled by Licensor in the Licensor Patent Rights and Licensor Know-How; provided, however, that the foregoing shall exclude the Excluded Technology.

Product shall mean (i) with regard to the Option Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to a Product Antigen or (b) Genetic Material encoding such an Antibody, wherein in respect of each Product, said Genetic Material does not encode multiple Antibodies; and (ii) with regard to a Product License Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to the Product Antigen (as defined in such Product License Agreement) or (b) Genetic Material encoding such an Antibody wherein, in respect of each Product, said Genetic Material does not encode multiple Antibodies.

Product Antigen shall mean (i) with regard to the Option Agreement, a Permitted Antigen as to which Licensee has obtained an Option, as further described in the Option Agreement; and (ii) with regard to a Product License Agreement, the Antigen described in the Product License Agreement.

Xenomouse Animals shall mean transgenic mice which are Controlled by Licensor and which contain unrearranged human immunoglobulin genes that are capable of producing human antibodies when immunized with an antigen.

XenoMouseâ„¢ is a leading technology for generating fully human antibody drugs useful in treating a wide range of diseases.

Field of Use
Field shall mean the use of Products (i) for human therapeutic, prophylactic and diagnostic medical purposes and as laboratory research reagen.

XenoMouseâ„¢ is a technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.

Research Field shall mean the immunization of XenoMouse Animals with Permitted Antigens, the use of materials derived or generated in whole or in part from such XenoMouse Animals that are so immunized, and the use of the XenoMouse Animals themselves, solely for the creation, identification, analysis, manufacture, research, and preclinical development of Products in the Field. For purposes of clarification, it is understood that 'immunization' of XenoMouse Animals with a Permitted Antigen includes the immunization of XenoMouse Animals with any formulation or construction of a Permitted Antigen, regardless of the three dimensional configuration of such Permitted Antigen, including, but not limited to, cell lines expressing such Permitted Antigen on their cell surface and chimeric molecules containing such Permitted Antigen; provided, however, that any research, development or use of Antibodies that bind to an excluded Antigen (other than to determine whether they bind to a Permitted Antigen) shall be outside of the scope of the licenses granted under the Option Agreement.

IPSCIO Record ID: 227247

License Grant
Subject to Third Party rights the United Kingdom Licensor, government organization, grants to the United Kingdom Licensee during the continuance of this Agreement the following rights and licenses under the Patent Rights and the Technology on the following conditions
For the Exclusive Rights
Licensor grants the exclusive right and license under Licensee License Conditions to identify, develop, make, have made, import, market and sell selective antibodies for human in vivo use and includes using an antibody gene as a therapeutic entity in gene therapy provided always that Licensee will grant up to six exclusive sub-licenses to develop, make, have made, use, import, market and sell a specific antibody product directed at a particular antigen, for the avoidance of doubt it is declared antibodies derived from  SCID Hu mice would count within this total, to the Collaborative Centre, but excluding any right of access or license to use Licensee Libraries, with the right for the Collaborative Centre to sub-sub license for royalties payable by the Collaborative Centre to Licensee and on financial terms.

And, the exclusive right and license under Licensee License Conditions to use antibodies as part of a medical, but not a research, procedure involving in vitro selection of Rare Cell Population for therapy or diagnosis.

And, the exclusive right and license under Licensee License Conditions to provide Antibody Isolation Services for third parties.

And, the exclusive right and license under Licensee License Conditions to use and exploit commercially in any way whatsoever the inventions the subject of the patent and its corresponding patents for Diabodies except in the following fields of use
(a) biosensors;
(b) therapeutic products which include mammalian retroviruses encoding diabodies as a fusion with viral coat proteins; and
(c) diabodies generated from combinations of four specific antibodies.

And, the exclusive right and license under Licensee License Conditions to use molecules isolated by the Technology for use in the manufacturing process of pharmaceutical products or intermediates.

And, the exclusive right and license under Licensee License Conditions to develop, make, have made, use, import, market and sell Catalytic Antibodies or Research Products.

And, for Co-exclusive rights
the co-exclusive right and license for Licensee under Licensee License Conditions to improve. develop, make, have made, import, market and sell antibodies originally isolated by hybridoma derived methods from non-primate sources which have been humanized using CDR grafting techniques the subject of the patent known as Winter l, derived from the UK Patent application UK 860 7679 filed 27 March 1986-and US Parent Application 903776.

And, the co-exclusive right and license for Licensee under Licensee License Conditions to use antibody structural information to design non-antibody drug candidates.

And, for Gene-sequencing and analysis rights,  the exclusive right and license under Licensee License Conditions to use antibody repertoires and libraries and antibodies isolated from them in the identification, analysis and validation of targets for therapeutic, diagnostic or prophylactic entities arising from gene sequencing data and analysis provided always that Licensor shall have the right, which for the avoidance of doubt it is declared and agreed does not include any right of access to or license to use the Licensee Libraries, to grant collaborative licenses.

And, for the Third Party License, a non-exclusive license to third party companies who are licensed by Licensor to use and exploit other Licensor pending or granted patent rights or technology which third
parties focus and which other Licensor rights are not principally in the field of therapeutic antibodies.

And, for the non-exclusive rights,  the non exclusive right and license under Licensee License Conditions for all purposes other than those specifically excluded.

This Party agreement is, in relation to such a target, an exclusive license to develop, make, have made, market and sell only therapeutic antibodies to any such target; and, in relation to such a Product which is an actual or potential therapeutic antibody an exclusive license to develop, make, have made, market and sell only such therapeutic antibody.

License Property
Products means any product or formulation whose development, manufacture, use or sale would, absent a license, infringe the Patent Rights or utilize the Technology.

Catalytic Antibodies means antibodies which bind to and catalyze the chemical transformation of a substrate and in which an antibody binding region is involved in said catalysis.

Patents include Cloning Immunoglobulin Variable Domain Sequences; Methods for producing members of specific binding pairs; Production of chimaeric antibodies, a combinational approach; Production of anti-self antibodies from antibody segment repertoires and displayed on phage; Methods for producing members of specific binding pairs; SBP members with a chemical moiety covalently bound within the binding site production and selection thereof; Recombinant Binding Proteins and Peptides; and, Treatment of cell populations.

Field of Use
The use of the antibodies is intended for medical procedure, not research.  

The third party rights are for the field of human drug therapy by antibodies directed against the CD4-binding domain of the HIV-1 gp 120 protein.

IPSCIO Record ID: 243460

License Grant
The Irish Licensor grants to the Licensee of England a worldwide, non-exclusive, non-transferable license, solely on its own behalf and on behalf of any Licensee Collaborator, without any right to sublicense, under the Licensor Patent Rights to
(a) Make or have made Licensed Antibody Phage Display Materials;
(b) Solely for Research and Development purposes, conduct Antibody Phage Display;
(c) Make or have made Research Quantities of a Licensed Immunoglobulin;
(d) Transfer Antibody Phage Display Materials, Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Licensee Collaborator; and
( e) Use, sell, offer to sell, import and export Licensed Immunoglobulins.
License Property
The patents include Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use, and, Modular Assembly of Antibody Genes, Antibodies, and, Novel Plasmid Vector with Pectate Lyase Signal Sequence.

Antibody Phage Display means the authorized use of Licensed Antibody Phage Display Materials to conduct Research and Development.

Licensed Antibody Phage Display Materials means any collection or library of polynucleotide sequences, including without limitation a Licensee Library, created by Licensee and under the exclusive control of Licensee, which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage, including without limitation a Licensee Library, created by or under the exclusive control of Licensee, wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin and an outer surface polypeptide of a bacteriophage.

Licensed Immunoglobulin means any Immunoglobulin discovered, isolated or characterized by Licensee or a Licensee Collaborator through the use of Licensed Antibody Phage Display Materials.

Field of Use
The field is antibody drug discovery.

IPSCIO Record ID: 114137

License Grant
Licensee transferred certain products to the Scottish Licensor to apply it's technology and know-how to perform Delmmunisation.
License Property
Products shall mean and include Monoclonal Antibodies and IFN Products.

Monoclonal Antibodies shall mean and include collectively certain monoclonal antibodies specific for certain antigens and the cell lines which produce them (and which Licensee has the right to develop and commercialize) such Monoclonal Antibodies being  described more specifically in the Materials Transfer Agreement between the parties dated March 17, 1999, or otherwise specified as provided by Licensee pursuant to this Agreement.

IFN Products shall mean and include interferon and/or fusion proteins with interferon conjugated to an immunoglobulin Fc, preferably through a peptide linker, and the expression system therefor, as generally described in U.S. Patent No. 5,723,125 (IFN product), assigned to Licensee.

PRODUCTS
                                                        ISOTYPE OF STARTING
DESIGNATED NAME                     ANTIGEN                      ANTIBODY
—————                                         ——-                         ——————-
(1) 5D12                                            CD40                         Human IgG4

(2) 5A8                                               CD4                           Human IgG4

(3) 166-93                                          G-CSF Receptor      Murine IgG1
  
(4) 166-32 or                                      Factor D                   Human IgG1
                                                             IFNa-Fc                    Human IgG4

Delmmunised is the procedure using the technology, materials and know-how for the genetic engineering which removes potentially immunogenic sequences in the variable region of antibodies and introduces human constant regions to produce an antibody for therapeutic or In Vivo diagnostic purposes designed to avoid or substantially minimize immunogenic response In Vivo.

The technology is described in International Patent Application PCT/GB98/01473

Field of Use
This agreement pertains to the medical industry relating to antibodies for therapeutic or In Vivo diagnostic purposes.

IPSCIO Record ID: 202852

License Grant
Licensor shall nominate the Antigen under a Master Research License and Option Agreement and obtain the right to obtain a Product License Agreement with respect to the Antigen for commercial use by Licensee.

For commercial license, Licensor shall grant an exclusive license or sublicense, as the case may be, with the right to grant sublicenses, under the Licensed Technology, to make and use Research Program Materials and Information solely to make and have made Product and to use, sell, lease, offer to sell or lease, import, export, otherwise transfer physical possession of or otherwise transfer title to Product, in the Territory for use in the Field.

License Property
The Antigen is known as properdin, as described in U.S. Patent Application No. 09/138,723 and PCT Application No. WO98/17500.

Licensor has rights in certain strains of transgenic mice, XenoMouse(TM) mice, that are capable of producing human antibodies when immunized with an antigen.

'PRODUCT' shall mean any dosage or formulation of a product comprising an Antibody which binds to the Antigen.

Field of Use
Licensee will use Licensor's XenoMouse(R) technology to generate fully human monoclonal antibodies to the complement protein properdin. These human monoclonal antibodies are being designed for use in the fields of cardiovascular and inflammatory diseases.

IPSCIO Record ID: 273384

License Grant
Sellers hereby grants to Buyer an exclusive, limited to the Anthrax Field, worldwide, perpetual license under the Technology to Develop and Commercialize Products intended for use in the Anthrax Field, with the right to grant sublicenses.
License Property
Technology means Know-How or intellectual property owned, or licensed, by Seller reasonably necessary or useful in connection with the development or commercialization of pharmaceutical products incorporating human monoclonal antibodies.

The AVP Anthrax Patents constitute all patents and patent applications owned by Sellers necessary or useful for the exploitation of the Product and the conduct of the Product Line Operations.

Licensed Product means the Product as licensed or approved by any applicable Regulatory Authority or any product Developed or Commercialized under a sublicense of the rights granted under the Asset License in this Agreement.

Field of Use
Buyer received a limited exclusive license to use Sellers's proprietary Xenerexâ„¢ Technology platform to develop future human monoclonal antibodies targeted against Bacillus anthracis.

IPSCIO Record ID: 256262

License Grant
The Licensors grant an exclusive license in the Territory under the Licensed Patents and Information for all  purposes, including without limitation, to develop, use, make, have made, import, have imported, export, have exported, offer for sale, have sold and sell Licensed Products.
License Property
The patents are for anti-fibrotic uses of Pirfenidon.  

'Licensed Patents' means that certain U.S. Patent No. 5,310,562 with respect to the anti-fibrotic uses of Pirfenidon.

Field of Use
The field of use is for the therapeutic treatment of a specific fibrotic human disease.
The Licensee licensed the rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis.
Fibrosis, or the accumulation of extracellular matrix molecules that make up scar tissue, is a common feature of chronic tissue injury. Pulmonary fibrosis, renal fibrosis, and hepatic cirrhosis are among the more common fibrotic diseases, which in aggregate represent a huge unmet clinical need.

IPSCIO Record ID: 372444

License Grant
The existing agreement is for the rights to use Licensor’s antibody phage display technology.  This agreement is to extend the term  and amend other terms.

Licensee shall have rights to use and practice the Licensor Technology, and Licensor licensed Patent Rights and Know-How as follows
— For the Licensor Antibody library, Licensor grants to Licensee a world-wide, nonexclusive license, without the right to grant sublicenses, to use the Licensor Antibody Library and to practice the Licensor Patent Rights solely in connection with the use of the Licensor Antibody Library to research, develop and make Antibody Compounds and a world-wide, nonexclusive license, with the right to sublicense, to use the Antibody Compounds in order to make, have made, use, sell or import Licensed Products.

For Licensor Materials, In connection with the practice of the license rights set forth, Licensor grants to Licensee a worldwide, non-exclusive, non-transferable license, without the right to grant sublicenses, to use the Licensor Materials on its own behalf only to identify Antibody Compounds from the Licensor Antibody Library and to make quantities of Antibody Compounds that are reasonably required for research and development activities only.

For the Third Party Sublicense Rights, During the library License Term, Licensee shall have rights to use and practice the Licensor licensed Patent Rights and Know-How.

License Property
Licensor possesses intellectual property and know-how related to, among other things, the discovery of antibodies having novel binding properties using phage display.

Licensed Product means any Antibody Compound or product that incorporates an Antibody Compound, whether or not conjugated to another compound that is a Therapeutic Product or an In Vitro Diagnostic Product.

The licensed library is The phagemid-based Fab library.

Licensed materials include Expression vectors pXPlsacB and pXP2sacB for soluble Fab production in E. coli. IgG expression vectors (pBRV and pShuttle) for rapid subclomng and converting Fab fragments into human IgGl and IgG4 and munne IgG2a. (Streptavidin-binding antibody clones will be provided as a positive control.)

The patents include
— Phage display patents
— Focused libraries of genetic packages
— Novel methods of constricting libraries of human FAB antibody fragments displayed on filamentous phage
— Ligand Screening and Discovery
— Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use
— Novel Plasmid Vector with Pectate Lyase Signal Sequence

Field of Use
The field of use is Therapeutic Field of Use means shall mean human therapeutics only and not for any in vitro or in vivo diagnostics, purification or separations, research products nor for any other purposes.

IPSCIO Record ID: 357950

License Grant
Licensor grants to Licensee, an affiliate, an exclusive, worldwide right and license, with the right to sublicense, under the Licensed Patents to research, Develop, manufacture, have manufactured, use, import and Commercialize and have Commercialized the Licensed Products, in and for the Field and to practice and have practiced any Licensed Processes, in and for the Field.

Effective immediately at the time Licensee is no longer deemed to be an Affiliate of Licensor, Licensor grants Licensee a non-exclusive license under Licensed rights in and to the Licensed Materials solely in support of the exercise of Licensees license rights.  Licensee shall not have the right and shall be prohibited from selling, transferring, or distributing the Licensed Materials to end users, except in the case where such end users are Licensor Affiliates or Sub licensees under this Agreement.

License Property
Licensor has rights to the Licensed Patents and Materials as granted by Dana Farber Cancer Institute.

Antibody means any antibody, any gene expressing such an antibody, any hybridoma producing such antibody, or any fragment, variant, derivative or construct thereof, or antibody fusion protein produced therefrom, including PEDgylated or multimeric versions thereof, whether polyclonal, monoclonal, multi-specific antibodies, e.g., bi-specific antibodies, human, humanized, chimeric, murine, synthetic, or from any other source, including without limitation, the full immunoglobin molecules (e.g. the IgG, IgM,IgE, IgA, and IgD molecules), and the antigen binding portions including Fab, Fab, F(ab)2, Fv, dAb, and CDR fragments, chimeric antibodies, diabodies, polypeptides, linear antibodies and single-chain antibodies (scFv) that contain any portion of an immunoglobulin that is sufficient to confer specific binding to an antigen.

The agreement is to develop and commercialize Licensor's fully human anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.

Field of Use
The Field means all prophylactic, palliative, therapeutic or diagnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemias, Lymphomas, Multiple Myeloma and Waldentroms Macroglobulemia, but specifically excluding use in chimeric antigen receptor technology. Additionally, upon exercise of the Autoimmune Option, the Field shall include the prevention, diagnosis and treatment of Autoimmune Diseases.

Autoimmune Diseases means any disease which results from a loss of immune tolerance to self-antigens, including without limitation multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, sjogren syndrome, celiac disease, Graves disease, myasthenia gravis, Type I diabetes, idiopathic thrombocytopenic purpura, pemphigus vulgaris, among others, including any presentation or manifestation thereof.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.